Kaiser Permanente Wegovy and Zepbound Coverage: Who Still Qualifies in 2026

Kaiser Permanente will cover Wegovy or Zepbound for weight loss only in plans and regions that explicitly include an anti-obesity drug benefit, and even then members must meet strict body-mass-index and comorbidity criteria plus fail older weight-loss drugs first. In regions such as Washington, commercial plans list Wegovy as “not covered,” while the Northwest region allows Wegovy or Zepbound for 12 months if you have the weight-loss rider and clear step-therapy rules. Everyone else must pay cash, appeal, or look to manufacturer programs or the new Medicare GLP-1 Bridge.

• Kaiser Permanente Washington declared Wegovy “not covered” on its commercial formulary in January 2026. (wa-provider.kaiserpermanente.org)
• In the Northwest, Wegovy is formulary if the plan covers weight-loss drugs and the member has BMI ≥30 kg/m² (or ≥27 with a comorbidity) and has failed at least two older agents. (healthy.kaiserpermanente.org)
• Zepbound is non-formulary in the Northwest and requires a six-month semaglutide trial before approval. (healthy.kaiserpermanente.org)
• Cash-pay through NovoCare is $199 per box for the first two doses, then $349 per month for Wegovy injections up to 2.4 mg. (novocare.com)
• LillyDirect lists Zepbound at $299 per month for 2.5 mg vials and up to $699 per month for higher doses, with as-low-as $25 offers for insured users. (zepbound.lilly.com)
• Starting July 1, 2026, Medicare’s GLP-1 Bridge caps eligible beneficiaries’ cost at $50 per month for Wegovy tablet, Wegovy injection, or Zepbound KwikPen. (cms.gov)

How Kaiser Permanente sets GLP-1 rules

Kaiser Permanente is a nonprofit integrated health system with nine independently licensed regional health plans. Each region’s Pharmacy & Therapeutics Committee decides whether a medication like Wegovy or Zepbound appears on its formulary and what criteria apply. That decentralization explains why a member in California may get a Wegovy approval while a member in Washington is denied. Kaiser’s internal CORB and CBC programs publish the criteria PDFs that prescribers must follow. (healthy.kaiserpermanente.org)

2026 formulary status by region

The table below summarizes where Wegovy and Zepbound stand as of October 2026. Always confirm with Member Services because employer groups and small-business plans can carve out their own benefits.

What the 2026 prior-authorization forms require

If your Kaiser plan does cover Wegovy or Zepbound, approval hinges on six main checkpoints. The Northwest criteria are representative:

• Active weight-loss benefit: Your pharmacy rider must cover anti-obesity drugs. No rider, no approval. (healthy.kaiserpermanente.org)
• Body-mass index: Adults need BMI ≥30 kg/m², or ≥27 with an approved comorbidity such as hypertension, type 2 diabetes, or OSA. (healthy.kaiserpermanente.org)
• Lifestyle documentation: The prescriber must attest that you are following diet and exercise counseling or have a behavioral-health referral. (healthy.kaiserpermanente.org)
• Step therapy: At least two older agents (phentermine, Qsymia, Contrave, topiramate) tried for three months each. (healthy.kaiserpermanente.org)
• Semaglutide failure before Zepbound: Zepbound is allowed only after a six-month Wegovy or Ozempic trial or documented intolerance. (healthy.kaiserpermanente.org)
• 12-month re-review: You must show ongoing weight loss (usually ≥5% of baseline) for renewal. (healthy.kaiserpermanente.org)

Cheapest alternatives if Kaiser denies coverage

Denied members still have several cost-cutting paths.

Manufacturer self-pay programs: NovoCare ships Wegovy for $199 per month for the first two boxes, then $349 for most doses, or $399 for Wegovy HD 7.2 mg. (novocare.com) LillyDirect prices Zepbound at $299 for 2.5 mg and up to $699 for higher doses, with $25 copay cards for eligible insured users. (zepbound.lilly.com)

Medicare GLP-1 Bridge: Starting July 1 2026, eligible Part D enrollees pay $50 per month for Wegovy (injection or tablet) or Zepbound KwikPen during the two-year bridge period. (cms.gov)

Appeal with new evidence: A cardiologist note documenting established cardiovascular disease may support a Wegovy request for risk-reduction labeling, which some regions cover under the medical, not weight-loss, benefit.

Switch insurers during open enrollment: Marketplace “Silver 87” plans from other carriers may include anti-obesity coverage; verify formularies before switching.

Cash-pay at retail pharmacies: Novo Nordisk’s current list price for Wegovy is $1,349 per box. Using a free Rx.com discount card may trim several hundred dollars but rarely beats the manufacturer programs.

How to appeal or request an exception

Kaiser members have three escalating options.

1. Coverage exception request: Your prescriber submits Kaiser’s Pharmacy Prior Authorization Request form with medical rationale. Include BMI logs, failed-drug dates, and adverse-effect notes.

2. Internal appeal: If denied, file a written appeal within 180 days. Kaiser’s Utilization Management department must respond within 30 days for standard requests or 72 hours for urgent ones. (healthy.kaiserpermanente.org)

3. External review: In most states, an independent review organization can overturn the denial if medical necessity is proven.

What the Medicare GLP-1 Bridge means for Kaiser retirees

Retirees with Kaiser Medicare Advantage plans can bypass Kaiser’s own formulary rules through the federal bridge. The CMS program pays pharmacies directly, so Kaiser bills nothing to the member’s Part D plan.